Kodiak Sciences Inc (KOD)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow KOD in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on KOD and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
KOD at a glance
Key statistics
$5.84B
Market capitalization
- Previous close
- $92.97
- Open
- $91.25
- Day range
- $89.15 – $94.88
- Volume
- 552.1K
- Average volume (30 sessions)
- 2.93M
- Shares outstanding
- 62.85M
- Earnings per share
- $(3.85)
- Price / book
- 95.6
- Beta (1 year, vs SPY)
- 0.05
Where the price sits in its year
52-week range
84% of the range
- Below the 52-week high
- -13.8%
- Above the 52-week low
- +466.5%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $83.37+11.5%
- 50-day average
- $55.52+67.5%
- 200-day average
- $39.48+135.5%
Between the conventional 30 and 70 bands.
+1.5%
1 week
+186.8%
1 month
+121.8%
3 months
+232.5%
Year to date
+559.4%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with KOD
KOD on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on KOD.
See the plans →
Every planScreen names like KOD
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on KOD
Put KOD on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on KOD
See whether there is an open premium alert on KOD, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
KOD headlines
- Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday
Benzinga · Sep 25, 2025
- Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · Mar 28, 2024
- Expert Ratings for Kodiak Sciences
Benzinga · Jul 27, 2023
SEC Form 4, most recent first
Insider filings
BAKER BROS. ADVISORS LP
+82.7K
Director, 10% owner · Open-market purchase
$7.41M · Sep 28, 2026
667, L.P.
+39
Director, 10% owner · Open-market purchase
$3.19K · Sep 28, 2026
667, L.P.
+63.5K
Director, 10% owner · Open-market purchase
$5.52M · Sep 28, 2026
667, L.P.
+78.7K
Director, 10% owner · Open-market purchase
$5.75M · Sep 28, 2026
BAKER BROS. ADVISORS LP
+123.9K
Director, 10% owner · Open-market purchase
$10.40M · Sep 28, 2026
Baker Brothers Life Sciences LP
+279.0K
Director, 10% owner · Open-market purchase
$20.19M · Sep 28, 2026
BAKER JULIAN
+884
Director, 10% owner · Open-market purchase
$70.46K · Sep 28, 2026
Baker Bros. Advisors (GP) LLC
+3.8K
Director, 10% owner · Open-market purchase
$329.51K · Sep 28, 2026
About Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Palo Alto, CA
- Employees
- 124
- Listed since
- Oct 4, 2018
- Website
- kodiak.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.